Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
about
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Cancer vaccines and T cell therapyRecent advance in antigen-specific immunotherapy for acute myeloid leukemiaEvaluation of current cancer immunotherapy: hemato-oncologyActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsT Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical OutcomeGraft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide geneSalvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID miceImmune-based therapeutics for pediatric cancer.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Bispecific antibodies engage T cells for antitumor immunotherapy.Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotAdoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantAdoptive T cell therapy of cancer.Haematological malignancies: at the forefront of immunotherapeutic innovation.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Cellular therapies in acute lymphoblastic leukemiaAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategiesImmunotherapy for pediatric leukemia.Evaluation of TCR repertoire diversity in patients after hematopoietic stem cell transplantation.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunityBiologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantationThe biological basis for immunotherapy in patients with chronic myelogenous leukemia.Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia.WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Adoptive T-cell therapy for B-cell malignancies.
P2860
Q26775720-E3F6EF81-B863-4810-BB17-08E92B883E5DQ26830857-4033C794-B2B0-441D-8CC3-106A1B6B6480Q26995638-AC490D7C-018A-43DA-AD78-DE436F8457D5Q27005765-8839D8D4-25D6-4133-B863-661115D126CEQ27006179-D181643C-886F-4BB4-8D61-18DC6512F08FQ27026836-554AFD12-FE6B-4434-9094-36FACEC0AA85Q28072227-E0EEC2A9-7595-46C4-99C7-9D249A524E49Q30537403-71093F9C-30A8-40C2-B861-23C0B8B9AB8DQ33416874-44338D7A-DB3B-4723-85F1-B53C01A8B7B6Q33587590-F05E7BD2-1E09-4E49-BB1A-7E629FE566A8Q33604121-C1E17857-61AA-4D16-B5D5-A04925786598Q34022415-8D472F54-5FA7-4F52-AC45-B092A9FD691AQ34174334-DCA4605C-9EF4-4A54-99FA-9635344723FBQ34180369-19987C4D-035B-4EC7-A078-1D0568927B14Q34279672-F38EB805-AD64-4C1A-AF9C-494438D7D1D8Q34612637-EE332849-B5E1-4CBA-AF01-86A1BA3C9342Q34616701-5CE7D82A-91C6-449A-83E9-1118212772F1Q34635978-0042C3A7-B43F-4F3E-95A8-1B65D41AAE9BQ34977470-7528C916-8AEE-4C37-A4B0-3E64F61B1EFEQ35880618-AD94241F-CFB6-4BD9-B2C1-B063D83161F2Q35889240-DB3E0B06-BD6C-4DCC-AFDC-8C5BF31877CFQ36384606-E5A81C6E-1B67-4C88-BE53-17EA99F2EE1AQ36552098-1445A6F6-CB48-4F4E-8660-2275CFDAD83CQ36662079-E5D2DB0B-6179-4A06-9FEF-B1CD1985156EQ36819337-643886EF-0CC0-43B4-AD57-6C70286CBF13Q36968163-32EF1D44-F80F-4383-B1AE-4E142D00A463Q37044023-07EAE3BB-1932-438F-98F4-6441C4904D29Q37061964-9CC36339-0CC9-41E2-8D0C-6AC96AC6A9FCQ37119922-6772061C-90CC-4EE9-9E5C-210C2C7402F0Q37132892-E22E8F7C-DA7F-45CD-8D65-C64869C97271Q37159243-1E247F74-9792-4EE1-AE87-9386413B7278Q37354189-218E56C3-2FCD-46BA-ADDA-CF986EA706E7Q37428671-7B74D82F-6332-45FA-80B0-C3CB7B207904Q37574653-881D884A-B2C0-48D0-A168-C47EF2A51B8CQ37613047-4A9BFD9A-A6E6-4E17-9422-0C87E51CF12BQ37635023-5739E906-F333-4963-951F-EDC4B44CD3EFQ37659113-250DEA3F-C298-4509-9FCB-7E04235846ABQ37731720-4BBE5BDF-E55C-4F7E-BF97-E0A0D67B1A66Q37810098-35756E01-7643-4DFA-960E-1D0B921606ACQ37810116-8A2508EA-EC4A-44F3-AE79-70957463CC01
P2860
Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@ast
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@en
type
label
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@ast
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@en
prefLabel
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@ast
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P1433
P1476
Graft-versus-leukemia effects ...... acute lymphoblastic leukemia.
@en
P2093
A John Barrett
Agnes S M Yong
Bipin N Savani
Daniel C Douek
Emma Gostick
Katayoun Rezvani
Keyvan Keyvanfar
P2860
P304
P356
10.1182/BLOOD-2007-03-076844
P407
P577
2007-05-15T00:00:00Z